{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:25Z","timestamp":1793136985541,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-025-03911-7","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:44:21Z","timestamp":1759232661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative efficacy of biologics for uncontrolled asthma patients with chronic rhinosinusitis or nasal polyps: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Akinari","family":"Tsukada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Tsurumaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Terada-Hirashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Takasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nokihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinyu","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"3911_CR1","unstructured":"Global initiative for asthma; 2024 GINA Main Report. Accessed 10 Nov 2024. https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf."},{"key":"3911_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","volume":"135","author":"PP Hekking","year":"2015","unstructured":"Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896\u2013902.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"3911_CR3","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","volume":"157","author":"E Wang","year":"2020","unstructured":"Wang E, Wechsler ME, Tran TN, et al. Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR). Chest. 2020;157(4):790\u2013804.","journal-title":"Chest"},{"issue":"1","key":"3911_CR4","doi-asserted-by":"publisher","first-page":"1800938","DOI":"10.1183\/13993003.00938-2018","volume":"53","author":"S Pavlidis","year":"2019","unstructured":"Pavlidis S, Takahashi K, Ng Kee Kwong F, et al. \u201cT2-high\u201d in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. Eur Respir J. 2019;53(1):1800938.","journal-title":"Eur Respir J"},{"issue":"1","key":"3911_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaip.2017.06.015","volume":"6","author":"M Matsusaka","year":"2018","unstructured":"Matsusaka M, Fukunaga K, Kabata H, Izuhara K, Asano K, Betsuyaku T. Subphenotypes of type 2 severe asthma in adults. J Allergy Clin Immunol Pract. 2018;6(1):274-276.e2.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"3911_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.anai.2023.08.021","volume":"132","author":"G Scelo","year":"2024","unstructured":"Scelo G, Torres-Duque CA, Maspero J, et al. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry. Ann Allergy Asthma Immunol. 2024;132(1):42\u201353.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3911_CR7","first-page":"37","volume":"33","author":"B Barroso","year":"2023","unstructured":"Barroso B, Valverde-Monge M, Alobid I, et al. Improvement in olfaction in patients with CRSwNP and severe asthma taking anti-IgE and Anti-IL-5 biologics: a real-life study. J Investig Allergol Clin Immunol. 2023;33(1):37\u201344.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"2","key":"3911_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12016-022-08938-w","volume":"64","author":"A Tiotiu","year":"2023","unstructured":"Tiotiu A, Mendez-Brea P, Ioan I, et al. Real-life effectiveness of benralizumab, mepolizumab and omalizumab in severe allergic asthma associated with nasal polyps. Clin Rev Allergy Immunol. 2023;64(2):179\u201392.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"3911_CR9","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","volume":"150","author":"A Akenroye","year":"2022","unstructured":"Akenroye A, Lassiter G, Jackson JW, et al. Comparative efficacy of mepolizumab, Benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis. J Allergy Clin Immunol. 2022;150(5):1097-1105.e12.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3911_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.anai.2022.12.018","volume":"130","author":"T Pitre","year":"2023","unstructured":"Pitre T, Jassal T, Angjeli A, et al. A comparison of the effectiveness of biologic therapies for asthma: a systematic review and network meta-analysis. Ann Allergy Asthma Immunol. 2023;130(5):595\u2013606.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"3911_CR11","doi-asserted-by":"publisher","first-page":"100934","DOI":"10.1016\/j.waojou.2024.100934","volume":"17","author":"H Kim","year":"2024","unstructured":"Kim H, Kim MG, Kim SR, et al. Comparative efficacy of biologics for patients with inadequately controlled asthma: a network meta-analysis. World Allergy Organ J. 2024;17(7):100934.","journal-title":"World Allergy Organ J"},{"key":"3911_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"3911_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","volume":"93","author":"R Brignardello-Petersen","year":"2018","unstructured":"Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36\u201344.","journal-title":"J Clin Epidemiol"},{"issue":"156","key":"3911_CR14","doi-asserted-by":"publisher","first-page":"190137","DOI":"10.1183\/16000617.0137-2019","volume":"29","author":"M Bonini","year":"2020","unstructured":"Bonini M, Di Paolo M, Bagnasco D, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020;29(156):190137.","journal-title":"Eur Respir Rev"},{"issue":"Suppl 3","key":"3911_CR15","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaci.2011.12.986","volume":"129","author":"RS Tepper","year":"2012","unstructured":"Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol. 2012;129(Suppl 3):S65\u201387.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"3911_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141\u201353.","journal-title":"Lancet Respir Med"},{"issue":"7414","key":"3911_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"3","key":"3911_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/bmjebm-2022-111928","volume":"28","author":"B Sadeghirad","year":"2023","unstructured":"Sadeghirad B, Foroutan F, Zoratti MJ, et al. Theory and practice of Bayesian and frequentist frameworks for network meta-analysis. BMJ Evid Based Med. 2023;28(3):204\u20139.","journal-title":"BMJ Evid Based Med"},{"key":"3911_CR19","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2147\/JAA.S413064","volume":"16","author":"TM Laidlaw","year":"2023","unstructured":"Laidlaw TM, Menzies-Gow A, Caveney S, et al. Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR. J Asthma Allergy. 2023;16:915\u201332.","journal-title":"J Asthma Allergy"},{"key":"3911_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/JAA.S288260","volume":"14","author":"C Emson","year":"2021","unstructured":"Emson C, Corren J, Sa\u0142apa K, Hellqvist \u00c5, Parnes JR, Colice G. Efficacy of tezepelumab in patients with severe, uncontrolled asthma with and without nasal polyposis: a post hoc analysis of the phase 2b PATHWAY study. J Asthma Allergy. 2021;14:91\u20139.","journal-title":"J Asthma Allergy"},{"issue":"2","key":"3911_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jaip.2019.07.016","volume":"8","author":"JF Maspero","year":"2020","unstructured":"Maspero JF, Katelaris CH, Busse WW, et al. Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2020;8(2):527-539.e9.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"S5","key":"3911_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/imj.58_13578","volume":"47","author":"C Katelaris","year":"2017","unstructured":"Katelaris C, Maspero J, Jayawardena S, et al. P58: dupilumab efficacy and effect on asthma control in patients with uncontrolled persistent asthma and comorbid chronic rhinosinusitis with or without nasal polyps. Intern Med J. 2017;47(S5):22.","journal-title":"Intern Med J"},{"issue":"1","key":"3911_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12931-021-01746-4","volume":"22","author":"PG Gibson","year":"2021","unstructured":"Gibson PG, Prazma CM, Chupp GL, et al. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respir Res. 2021;22(1):171.","journal-title":"Respir Res"},{"issue":"6","key":"3911_CR24","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","volume":"145","author":"P Howarth","year":"2020","unstructured":"Howarth P, Chupp G, Nelsen LM, et al. Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. J Allergy Clin Immunol. 2020;145(6):1713\u20135.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3911_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/all.14902","volume":"77","author":"GW Canonica","year":"2022","unstructured":"Canonica GW, Harrison TW, Chanez P, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy. 2022;77(1):150\u201361.","journal-title":"Allergy"},{"issue":"4","key":"3911_CR26","doi-asserted-by":"publisher","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","volume":"52","author":"ER Bleecker","year":"2018","unstructured":"Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52(4):1800936.","journal-title":"Eur Respir J"},{"issue":"3","key":"3911_CR27","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1164\/rccm.202305-0808OC","volume":"209","author":"ME Wechsler","year":"2024","unstructured":"Wechsler ME, Scelo G, Larenas-Linnemann DES, et al. Association between T2-related comorbidities and effectiveness of biologics in severe asthma. Am J Respir Crit Care Med. 2024;209(3):262\u201372.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3911_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00408-024-00715-0","volume":"202","author":"F Demolder","year":"2024","unstructured":"Demolder F, Vanderhelst E, Verbanck S, et al. Real-life response to biologics in severe asthma with nasal polyposis: insights from the Belgian Severe Asthma Registry. Lung. 2024;202(4):441\u20138.","journal-title":"Lung"},{"key":"3911_CR29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.anai.2024.06.033","volume":"133","author":"JA Bernstein","year":"2024","unstructured":"Bernstein JA, Silver J, Packnett, et al. Real World Unified Airway Benefits of mepolizumab; effectiveness in patients with asthma and comorbidity nasal polyps. Ann Allergy Asthma Immunol. 2024;133:422-429 e2.","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"5","key":"3911_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11882-023-01074-1","volume":"23","author":"E De Corso","year":"2023","unstructured":"De Corso E, D\u2019Amato M, Carpagnano GE, Pelaia G, et al. The comorbid patient in the spotlight: efficacy of Benralizumab on chronic rhinosinusitis with nasal polyp outcomes in presence of severe asthma. Curr Allergy Asthma Rep. 2023;23(5):237\u201348.","journal-title":"Curr Allergy Asthma Rep"},{"key":"3911_CR31","doi-asserted-by":"publisher","first-page":"881218","DOI":"10.3389\/falgy.2022.881218","volume":"3","author":"M D\u2019Amato","year":"2022","unstructured":"D\u2019Amato M, Menzella F, Altieri E, et al. Benralizumab in patients with severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: an ANANKE study post-hoc analysis. Front Allergy. 2022;3:881218.","journal-title":"Front Allergy"},{"issue":"2","key":"3911_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.alit.2020.01.001","volume":"69","author":"S Nakajima","year":"2020","unstructured":"Nakajima S, Kabata H, Kabashima K, Asano K. Anti-TSLP antibodies: targeting a master regulator of type 2 immune responses. Allergol Int. 2020;69(2):197\u2013203.","journal-title":"Allergol Int"},{"issue":"9","key":"3911_CR33","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1084\/jem.20051135","volume":"202","author":"T Ito","year":"2005","unstructured":"Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005;202(9):1213\u201323.","journal-title":"J Exp Med"},{"issue":"3","key":"3911_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000534902","volume":"185","author":"FJ Bravo-Guti\u00e9rrez","year":"2024","unstructured":"Bravo-Guti\u00e9rrez FJ, Miralles-L\u00f3pez JC, Valverde-Molina J, et al. Effectiveness of mepolizumab in patients with severe eosinophilic asthma with\/without nasal polyposis: a real-life study. Int Arch Allergy Immunol. 2024;185(3):253\u20139.","journal-title":"Int Arch Allergy Immunol"},{"issue":"12","key":"3911_CR35","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","volume":"9","author":"S Nolasco","year":"2021","unstructured":"Nolasco S, Crimi C, Pelaia C, et al. Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study. J Allergy Clin Immunol Pract. 2021;9(12):4371-4380.e4.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"3911_CR36","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/jpm12060976","volume":"12","author":"A Bakakos","year":"2022","unstructured":"Bakakos A, Schleich F, Bakakos P. Biological therapy of severe asthma and nasal polyps. J Pers Med. 2022;12(6):976.","journal-title":"J Pers Med"},{"key":"3911_CR37","unstructured":"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/tezspire-nasal-polyps-trial-met-primary-endpoints.html. Published 8 November 2024."},{"issue":"3","key":"3911_CR38","first-page":"678","volume":"12","author":"J Oykhman","year":"2024","unstructured":"Oykhman J, Nair P, Parhar K, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. J Allergy Clin Immunol Pract. 2024;12(3):678-688.e10.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"3911_CR39","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1111\/all.15792","volume":"78","author":"ID Pavord","year":"2023","unstructured":"Pavord ID, Bourdin A, Papi A, et al. Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose. Allergy. 2023;78(11):2921\u201332.","journal-title":"Allergy"},{"key":"3911_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/JAA.S328653","volume":"15","author":"AN Menzies-Gow","year":"2022","unstructured":"Menzies-Gow AN, McBrien C, Unni B, et al. real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study. J Asthma Allergy. 2022;15:63\u201378.","journal-title":"J Asthma Allergy"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03911-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03911-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03911-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:44:31Z","timestamp":1759232671000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03911-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3911"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03911-7","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"28 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.H. reports honoraria for lectures from AstraZeneca, GlaxoSmithKlein and Sanofi. The other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}